SPR Wins Fifth Consecutive Northeast Ohio Top Workplaces Award

SPR, a medical device company specializing in peripheral nerve stimulation (PNS) for pain management, has been named a Top Workplace by Northeast Ohio Top Workplaces for the fifth consecutive year. The recognition reflects the company's strong workplace culture amid significant growth, including doubled employee count and surpassed 50,000 patients treated with its SPRINT PNS System. SPR announced that Medtronic intends to acquire the company, a partnership expected to expand the SPRINT PNS reach to more patients.

06/29/2026, 9:00 AM • GlobeNewswire

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced its inclusion in the Russell 3000 Index and Russell 2000 Index following the 2026 Russell indexes reconstitution effective June 26, 2026. The biomedical company develops AVIM Therapy for hypertension in collaboration with Medtronic and Virtue SAB for atherosclerotic artery disease, both undergoing pivotal clinical trials.

06/29/2026, 8:00 AM • GlobeNewswire

3 Stocks I'm Not Selling No Matter What the Market Does

An investor outlines three dividend stocks he plans to hold through market downturns: Medtronic (a medical device company with 49 years of dividend increases), Realty Income (a REIT with 31 years of dividend growth and 5.2% yield), and Nucor (a steel maker with 50+ consecutive annual dividend hikes). The author argues that well-run companies remain well-run regardless of market conditions and represent solid long-term holdings.

06/27/2026, 6:15 PM • The Motley Fool

Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider

The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market, with the U.S. expected to grow from USD 3.16 billion to USD 8.17 billion by 2035.

06/27/2026, 4:30 AM • GlobeNewswire

2 High-Yield Dividend Stocks to Buy and Hold for a Decade

The article recommends Pfizer and Medtronic as attractive dividend stocks for long-term investors seeking portfolio stability amid economic uncertainties. Despite recent challenges, both healthcare leaders offer compelling dividend yields (6.8% and 3.6% respectively) and have strong pipelines and growth opportunities that could drive returns over the next decade.

06/23/2026, 4:30 PM • The Motley Fool

Healthcare Services Market Size to Worth USD 20.10 Trillion by 2035, Amid Rising Digital Healthcare Adoption – SNS Insider

The global healthcare services market is projected to grow from USD 8.62 trillion in 2025 to USD 20.10 trillion by 2035, with a CAGR of 8.87%. Growth is driven by rising chronic disease prevalence, aging populations, and digital healthcare adoption including telehealth and AI-enabled care. The U.S. market is expected to reach USD 4.93 trillion and Europe USD 6.25 trillion by 2035. Hospital services will dominate with 44% market share, while telehealth services will experience the fastest growth.

06/20/2026, 4:27 AM • GlobeNewswire

Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS Insider

The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.

06/19/2026, 5:09 AM • GlobeNewswire

Billionaire Ken Griffin Sold Amazon and Nvidia but Quietly Loaded Up on This Healthcare Giant

Ken Griffin's Citadel Advisors reduced positions in Nvidia and Amazon during Q1 while increasing its stake in Intuitive Surgical by 30.3%. Despite the medical device company facing headwinds from competition, lower margins on new products, and tariffs, analysts believe its strong competitive moat, large addressable market, and AI integration potential make it an attractive long-term investment at current valuations.

06/16/2026, 4:30 PM • The Motley Fool

3 Dividend Stocks to Hold for the Long Haul

The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.

06/16/2026, 6:15 AM • The Motley Fool

Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

Boston Scientific shares have plummeted over 50% year-to-date due to repeated downward guidance revisions, particularly regarding declining Watchman procedure usage. Despite bearish market sentiment, 27 of 31 analysts maintain buy ratings with a consensus price target of $78 (65% upside), though the article cautions this recovery may be challenging without faster-than-expected growth acceleration.

06/13/2026, 12:15 AM • The Motley Fool

ThruFlo Endovascular Secures Seed Funding to Advance First Purpose-Built Flow Diverter for Bifurcation Aneurysms

ThruFlo Endovascular announced completion of seed funding led by Atlas MedInnovation to develop a novel bifurcated flow diverter for treating cerebral aneurysms at vessel branch points. The device addresses a significant gap in the market where approximately 60% of intracranial aneurysms occur. Proceeds will fund R&D operations, device design completion, pre-clinical studies, and FDA IDE application submission.

06/10/2026, 3:40 PM • GlobeNewswire

5 Best Dividend Stocks to Own in Case the AI Trade Ends

As the AI boom may eventually fade, investors should diversify portfolios with dividend stocks from non-tech sectors. The article recommends five dividend-paying companies across real estate, fast food, consumer staples, home improvement, and healthcare that offer stable income and long-term growth potential.

06/10/2026, 4:05 AM • The Motley Fool

Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector

Medtronic reported its strongest growth in 10 years with 8.4% sales increase in fiscal 2026. The medical device maker offers an attractive investment combination: a 3.5% dividend yield (49-year streak of increases), low forward P/E multiple of 14, and diversified operations across 70 health conditions in 150+ countries. Despite being down 15% year-to-date, analysts view it as a compelling long-term buy in the healthcare sector.

06/08/2026, 10:30 AM • The Motley Fool

Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?

Medtronic received FDA approval for its Hugo robotic-assisted surgery platform for urologic procedures in December 2025, marking its entry into a market dominated by Intuitive Surgical's da Vinci system. While Medtronic faces significant competitive headwinds due to Intuitive's 26-year head start, massive installed base of 11,395 systems, and broader procedure approvals, the robotic surgery market is projected to grow from $13.8 billion to $63.7 billion by 2035. Medtronic's Hugo is already approved in 35+ countries with procedure volumes growing 2-3x faster than the market, suggesting the company can grow alongside the expanding market without necessarily overtaking the leader.

06/08/2026, 7:21 AM • The Motley Fool

Wall Street May Be Mispricing Medtronic, Analyst Says

Medtronic reported Q4 earnings that beat expectations with adjusted EPS of $1.55 and revenue of $9.81 billion, up 9.9% year-over-year. BTIG upgraded the stock from Neutral to Buy with a $90 price target, citing consistent organic growth and undervaluation relative to peers. Leerink Partners lowered its price target from $117 to $104 but maintains an Outperform rating, highlighting MDT as a Top Pick for 2026. Shares rose 4.30% to $81.30.

06/04/2026, 2:53 PM • Benzinga